FIG 2.

Lung CFU counts in C3HeB/FeJ mice after treatment. (A) Mice treated for 1 month with the BPaL regimen with or without an mTOR inhibitor or CC214-2 or rapamycin alone and for 2 months with the RHZE regimen with or without an mTOR inhibitor. No mice treated with rapamycin alone survived to the month 2 time point. (B) Relapse assessment after 15 weeks of treatment with RHZE with or without an mTOR inhibitor. (C) Relapse assessment after 11 weeks of treatment with BPaL with or without an mTOR inhibitor. The fractions above each regimen indicate the proportion of mice that relapsed after that treatment. Bars indicate median CFU numbers.